Sevelamer, a Phosphate-Binding Polymer, is a Non-Absorbed Compound
暂无分享,去创建一个
J. Petersen | M. Plone | S. Burke | Melissa A Plone | John S Petersen | David P Rosenbaum | Steven K Burke | D. Rosenbaum
[1] W. Goodman,et al. Aluminum accumulation during treatment with aluminum hydroxide and dialysis in children and young adults with chronic renal disease. , 1991 .
[2] E. Slatopolsky,et al. RenaGel, a nonabsorbed calcium- and aluminum-free phosphate binder, lowers serum phosphorus and parathyroid hormone. The RenaGel Study Group. , 1999, Kidney international.
[3] A. L. Sheffner,et al. The Disposition of Orally Administered Cholestyramine-C14 , 1965, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.
[4] J. L. Greger,et al. Excretion and retention of low or moderate levels of aluminium by human subjects. , 1983, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.
[5] A. Pierides,et al. Hemodialysis encephalopathy with osteomalacic fractures and muscle weakness. , 1980, Kidney international.
[6] F. Malberti,et al. Effect of chronic intravenous calcitriol on parathyroid function and set point of calcium in dialysis patients with refractory secondary hyperparathyroidism. , 1992, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[7] J. Delmez,et al. Calcium carbonate as a phosphate binder in patients with chronic renal failure undergoing dialysis. , 1986, The New England journal of medicine.
[8] B. Garrett,et al. A comparison of the calcium-free phosphate binder sevelamer hydrochloride with calcium acetate in the treatment of hyperphosphatemia in hemodialysis patients. , 1999, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[9] Burke,et al. Long-term effects of sevelamer hydrochloride on the calcium x phosphate product and lipid profile of haemodialysis patients , 1999, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[10] A. Alfrey. Aluminum Toxicity in Patients with Chronic Renal Failure , 1993, Therapeutic drug monitoring.
[11] L. Allen. Calcium bioavailability and absorption: a review. , 1982, The American journal of clinical nutrition.
[12] C. Hsu,et al. Are we mismanaging calcium and phosphate metabolism in renal failure? , 1997, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[13] T. Feest,et al. FRACTURING DIALYSIS OSTEODYSTROPHY AND DIALYSIS ENCEPHALOPATHY An Epidemiological Survey , 1979, The Lancet.
[14] B. Garrett,et al. A randomized trial of sevelamer hydrochloride (RenaGel) with and without supplemental calcium. Strategies for the control of hyperphosphatemia and hyperparathyroidism in hemodialysis patients. , 1999, Clinical nephrology.
[15] I. Huq,et al. Letters to the EditorAMPICILLIN-RESISTANT SHIGA BACILLUS IN BANGLADESH , 1974 .